Farxiga approved to reduce risk for CKD progression
(HealthDay)—Farxiga (dapagliflozin) oral tablets are now approved for adults with chronic kidney disease at risk for disease progression, the U.S. Food and Drug Administration announced Friday.
- Next story Investigating the role of Brd4 in diet-induced obesity
- Previous story HPV vaccination rates suboptimal within ages 9 to 12 years
Explore more
- AMD’s new Ryzen 3000 desktop APUs have arrived, starting at $259
AMD announced the release of several new products, including Ryzen Pro processors... - eReader Reviews
Unbiased eReader reviews by the experts, including the Amazon Kindle, Barnes &... - House Republicans vote to remove their conference chair, underscoring the party’s fealty to Trump
• ANALYSIS: Cheney shames colleagues who will purge her for disloyalty to... - This is the best place to buy a Dell laptop this Amazon Prime Day
The best place to find hot Prime Day deals on Dell laptops... - Richard Robinson Dies at 84; Turned Scholastic Into an Empire
With help from Harry Potter, the Magic School Bus and the Baby-Sitters... - F.D.A. Approves Alzheimer’s Drug Despite Fierce Debate Over Whether It Works
Aducanumab, or Aduhelm, is the first new Alzheimer’s treatment in 18 years... - Google fined $270 million in France for unfair advertising practices
Google will pay a €220 million ($270 million) fine and make changes... - At least 10% of the world’s giant sequoias lost in a single wildfire, report suggests
About 10 to 14% of the world’s giant sequoia trees were destroyed... - Top congressional leaders to meet with Biden for the first time in crucial week for his infrastructure plan
President Joe Biden faces a crucial moment on Wednesday in what is... - Why calculating the risk of the AstraZeneca vaccine is so difficult
Both the European Medicines Agency and the UK’s Medicines and Healthcare products...